Gynäkologische Onkologie

Die Erwartungen an den ASCO sind immer hoch, erwarten wir uns doch von diesem Kongress Erkenntnisse, die unseren Therapiestandard verändern. Manchmal erreichen uns aber auch Ergebnisse, die zeigen, dass der bisherige Standard seine Gültigkeit behält. Im Folgenden sind wichtige Ergebnisse für die gynäkologische Onkologie vom diesjährigen ASCO dargestellt.

The possibility for specific treatment of patients with ovarian cancer and shown BRCA1/2 mutation requires the evaluation of frequency of these mutations and if there are also other risk genes. Frequency ranges from 14 to 27 %. All germ line mutations can also be found in the tumor, additionally 4 % of mutations can only be found in tumor tissue. An other examination presented at ASCO 2016 showed that prolonging of the platinum free interval in intermediate platinum sensitive ovarian cancer with nonplatinum monotherapy does not improve survival, so that immediate platinum-containing therapy remains standard in recurrent ovarian cancer. The use of bevacizumab is still point of interest and is also safe in elder patients if side effects are closely monitored. Also the retreatment with bevacizumab after prior bevacizumab treatment can be administered safely. In vulvar cancer the isolated local recurrence worsens prognosis. Young patients with cervical cancer FIGO IB1 can be treated with less radical surgery without compromising the overall survival.

Key words

Gynaecology - oncology - ovarian cancer - germ line mutations - platinum-containing therapy - bevacizumab - vulvar cancer - cervical cancer

• Literatur

• 1 Kurian AW, Hughes E, Handorf E et al Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women. J Clin Oncol. 2016 34. (suppl; abstr 5510)
• 2 Harter P, Hauke J, Heitz F et al Incidence of germline mutations in risk genes including BRCA 1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). J Clin Oncol. 2016 34. (suppl; abstr 5538)
• 3 Hahnen E, Baumann KH, Heimbach A et al Prevalence of somatic mutations in risk genes including BRCA 1/2 in consecutive ovarian cancer patients (AGO-TR1 study). J Clin Oncol. 2016 34. (suppl; abstr 5544)
• 4 Selle F, Colombo N, Korach J et al Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (> 70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study. J Clin Oncol. 2016 34. (suppl; abstr 5535)
• 5 Coleman RL, Brady MF, Herzog TJ et al Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213. J Clin Oncol. 2016 34. (suppl; abstr 5523)
• 6 Pignata S, Scambia G, Raspagliesi F et al The MITO8-ENGOT OV1 phase 3 international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer (OC) recurring between 6 and 12 months after previous platinum based chemotherapy. A collaboration of MITO, MaNGO, AGO, BGOG, ENGOT, and GCIG. J Clin Oncol. 2016 34. (suppl; abstr 5505)
• 7 Woelber LL, Eulenburg C, Kosse J et al Prognosis after local recurrence in vulvar cancer: A subset analysis of the AGO-CaRE-1 study. J Clin Oncol. 2016 34. (suppl; abstr 5595)
• 8 Leitao MM, Sonoda Y, Gardner GJ et al Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. J Clin Oncol. 2016 34. (suppl; abstr 5525)